Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/203821
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease |
Autor: | Lahuerta, Juan José; Jiménez-Ubieto, Ana; Paiva, Bruno; Martínez-López, Joaquín; González-Medina, José; López-Anglada, Lucía; Cedena, Maria-Teresa; Puig, Noemi; Oriol, Albert; Blanchard, María Jesús; Ríos, Rafael; Martín, Jesús; Martínez, Rafael; Sureda, Anna; Hernandez, Miguel T.; Rubia, Javier de la; Krsnik, Isabel; Cabañas, Valentin; Palomera, Luis; Bargay, Joan; Mateos, Maria Victoria; Rosiñol, Laura; San Miguel, Jesús F. CSIC ORCID; Bladé, Joan | Palabras clave: | Brief Reports Clinical Trials and Observations CME article Free Research Articles Lymphoid Neoplasia Multiple myeloma Myeloid Neoplasia |
Fecha de publicación: | 20-jun-2019 | Editor: | American Society of Hematology | Citación: | Blood 133(25): 2664-2668 (2019) | Resumen: | Response criteria for multiple myeloma (MM) require monoclonal protein (M-protein)–negative status on both serum immunofixation electrophoresis (sIFE) and urine (uIFE) immunofixation electrophoresis for classification of complete response (CR). However, uIFE is not always performed for sIFE-negative patients. We analyzed M-protein evaluations from 384 MM patients (excluding those with light-chain-only disease) treated in the GEM2012MENOS65 (NCT01916252) trial to determine the uIFE-positive rate in patients who became sIFE-negative posttreatment and evaluate rates of minimal residual disease (MRD)–negative status and progression-free survival (PFS) among patients achieving CR, CR but without uIFE available (uncertain CR; uCR), or very good partial response (VGPR). Among 107 patients with M-protein exclusively in serum at diagnosis who became sIFE-negative posttreatment and who had uIFE available, the uIFE-positive rate was 0%. Among 161 patients with M-protein in both serum and urine at diagnosis who became sIFE-negative posttreatment, 3 (1.8%) were uIFE positive. Among patients achieving CR vs uCR, there were no significant differences in postconsolidation MRD-negative (<10−6; 76% vs 75%; P = .9) and 2-year PFS (85% vs 88%; P = .4) rates; rates were significantly lower among patients achieving VGPR. Our results suggest that uIFE is not necessary for defining CR in MM patients other than those with light-chain-only disease. | Versión del editor: | http://dx.doi.org/10.1182/blood.2019000671 | URI: | http://hdl.handle.net/10261/203821 | DOI: | 10.1182/blood.2019000671 | ISSN: | 0006-4971 | E-ISSN: | 1528-0020 |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
11
checked on 20-abr-2024
WEB OF SCIENCETM
Citations
10
checked on 29-feb-2024
Page view(s)
193
checked on 23-abr-2024
Download(s)
33
checked on 23-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.